Phil Taylor, Author at - Page 2 of 272

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Moderna says COVID booster works against Omicron subvariants

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron 0 Comment

Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against

Moderna says COVID booster works against Omicron subvariants

https://pharmaphorum.com/news/moderna-says-covid-booster-works-against-omicron-subvariants/

Digital/ News/ News

Pfizer is first big pharma to tap Truveta’s real-world data platform

Phil Taylor digital, digital health, electronic medical records, patient data, Pfizer, pharmacovigilance, real world data, Truveta 0 Comment

Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other

Pfizer is first big pharma to tap Truveta’s real-world data platform

https://pharmaphorum.com/news/pfizer-is-first-big-pharma-to-tap-truvetas-real-world-data-platform/

News/ News/ Sales and Marketing

Novartis faces threat of early generic of MS drug Gilenya in US

Phil Taylor generics, multiple sclerosis, Novartis, patent litigation 0 Comment

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after

Novartis faces threat of early generic of MS drug Gilenya in US

https://pharmaphorum.com/news/novartis-faces-threat-of-early-generic-of-ms-drug-gilenya-in-us/

News/ News/ R&D

Moderna facility in UK confirmed, part of 10-year deal with gov’t

Phil Taylor clinical trials, investment, manufacturing, Moderna, mRNA, NHS, R&D, UK 0 Comment

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead

Moderna facility in UK confirmed, part of 10-year deal with gov’t

https://pharmaphorum.com/news/moderna-facility-in-uk-confirmed-part-of-10-year-deal-with-govt/

News/ News/ R&D

Merck ups the stakes in pneumococcal jab face-off with Pfizer

Phil Taylor Merck & Co, Pfizer, pneumococcal disease, Prevnar 20, V116, vaccine, Vaxneuvance 0 Comment

Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the

Merck ups the stakes in pneumococcal jab face-off with Pfizer

https://pharmaphorum.com/news/merck-ups-the-stakes-in-pneumococcal-jab-face-off-with-pfizer/

News/ News/ Sales and Marketing

AbbVie files Qulipta for chronic migraine prevention

Phil Taylor AbbVie, Biohaven Pharmaceuticals, migraine, Nurtec ODT, Pfizer, prevention, Qulipta 0 Comment

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to

AbbVie files Qulipta for chronic migraine prevention

https://pharmaphorum.com/news/abbvie-files-qulipta-for-chronic-migraine-prevention/

News/ News/ R&D

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Phil Taylor antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, rare disease 0 Comment

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

https://pharmaphorum.com/news/az-preps-fda-filing-for-3-6bn-amyloidosis-drug-eplontersen/

Digital/ News/ News

Alimetry nabs FDA okay for gastric disorder-diagnosing wearable

Phil Taylor Alimetry, diagnosis, digital, digital health, Gastric Alimetry, gastrointestinal, wearable 0 Comment

New Zealand medical tech startup Alimetry has claimed an FDA approval for a wearable device that can be

Alimetry nabs FDA okay for gastric disorder-diagnosing wearable

https://pharmaphorum.com/news/alimetry-nabs-fda-okay-for-gastric-disorder-diagnosing-wearable/

News/ News/ Sales and Marketing

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

Phil Taylor AbbVie, Crohn's disease, inflammatory bowel disease, regulatory approval, Skyrizi 0 Comment

AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

https://pharmaphorum.com/news/abbvies-skyrizi-beats-il-23-rivals-to-crohns-disease-approval/

Trending

About Phil Taylor

Posts by Phil Taylor:

Moderna says COVID booster works against Omicron subvariants

Pfizer is first big pharma to tap Truveta’s real-world data platform

Novartis faces threat of early generic of MS drug Gilenya in US

Moderna facility in UK confirmed, part of 10-year deal with gov’t

Merck ups the stakes in pneumococcal jab face-off with Pfizer

AbbVie files Qulipta for chronic migraine prevention

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Alimetry nabs FDA okay for gastric disorder-diagnosing wearable

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

Trending

About Phil Taylor

Posts by Phil Taylor:

Login